Tie pharma CEO pay to fair global COVID-19 vaccine access, investors say
Reuters
Published Jan 06, 2022 03:11AM ET
Updated Jan 06, 2022 01:47PM ET
By Toby Sterling
AMSTERDAM (Reuters) -A group of institutional investors representing $3.5 trillion in assets under management on Thursday called on pharmaceutical companies to link their executives' pay to making COVID-19 vaccines available around the globe.
While the majority of citizens of wealthy nations are vaccinated and many are now receiving booster shots, across the African continent vaccination rates average only around 10%.
The World Health Organization has set a target of a 70% vaccination rate in every country by July 2022 in order to end the "acute phase" of the pandemic.
The 65 participating asset managers, pension funds and insurance companies signed a letter viewed by Reuters dated Jan. 4 that was sent to the boards of Pfizer Inc (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA) Inc and AstraZeneca (NASDAQ:AZN) Plc. The letter asks them to adopt a WHO roadmap for achieving equitable vaccine access and tying it to management pay "in a meaningful, material, measurable and transparent way".
Vaccine deliveries worldwide have been delayed by production problems, hoarding by governments of rich countries, export restrictions and red tape.
The investor group said key points include better participation in international vaccine programs and licensing and sharing technology so countries can produce vaccines locally.
"It should make business sense for a vaccine manufacturer to aim to vaccinate the whole world," said Frank Wagemans of Achmea Investment Management, one of the backers of the initiative with $225 billion in assets under management.
Other participating investors include Nomura, Investec, Boston Common Asset Management, Candriam, GAM, Aegon (NYSE:AEG) and PGGM.
Moderna could not immediately be reached for comment.
A spokesperson for Pfizer said the company and partner BioNTech had met a goal to deliver 1 billion doses to low and middle income countries in 2021 and would do so again in 2022.
Johnson & Johnson said in reaction that 60% of its vaccine has been shipped to low and middle income countries as of the end of 2021, and the company is in talks on a licensing agreement with Aspen Pharmacare (OTC:APNHY) to produce vaccine in South Africa.
A spokesperson for AstraZeneca said the company has distributed most of its supply to low and middle income countries, and it does so for no profit in those countries.
Peter Singer, Special Advisor to the Secretary General of the WHO, said the investor initiative was "extremely welcome".
The current unequal vaccine distribution represents "not only a complete moral failure for the world but also a very significant economic failure and a significant drag on the world economy", he said.
Get The News You Want
Achmea's Wagemans said he believed vaccine makers will generally be receptive to the request but the fund manager will look at how the companies put promises into action before their annual meetings.
"I cannot speak for the other signatories as to how they will vote, but for Achmea management, yes, we will vote against (executive pay packages) if there's no link made" to the WHO roadmap, he said.
($1 = 0.8843 euros)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.